• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表皮生长因子受体抑制剂(EGFRI)皮肤毒性的临床管理:护理视角

Clinical management of EGFRI dermatologic toxicities: the nursing perspective.

作者信息

Purdom Michelle, Ohinata Aki

机构信息

Division of Cancer Medicine, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA.

出版信息

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):29-30.

PMID:18154215
Abstract

All nursing personnel actively participate in the nursing process, with the registered nurse taking primary responsibility. Five steps in the nursing process include assessment, diagnosis, planning, implementation, and evaluation. Health-care professionals have more than 10 years of experience with EGFR inhibitors in the oncology setting. To date, the application of the nursing process to assist in patient management has not been previously published or thoroughly described in the literature. This article will apply the nursing process utilizing current recommendations regarding the assessment and management of dermatologic toxicities associated with EGFR inhibitors.

摘要

所有护理人员都积极参与护理过程,注册护士承担主要责任。护理过程的五个步骤包括评估、诊断、计划、实施和评价。医疗保健专业人员在肿瘤学领域使用表皮生长因子受体(EGFR)抑制剂已有10多年的经验。迄今为止,在文献中尚未发表或详细描述过应用护理过程来协助患者管理。本文将运用护理过程,采用有关EGFR抑制剂相关皮肤毒性评估和管理的当前建议。

相似文献

1
Clinical management of EGFRI dermatologic toxicities: the nursing perspective.表皮生长因子受体抑制剂(EGFRI)皮肤毒性的临床管理:护理视角
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):29-30.
2
Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.表皮生长因子受体抑制剂(EGFRI)相关皮肤毒性的临床管理:药学视角
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):31-3.
3
Clinical management of EGFRI dermatologic toxicities: US perspective.表皮生长因子受体抑制剂(EGFRI)皮肤毒性的临床管理:美国视角
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):17-21.
4
Clinical management of EGFRI dermatologic toxicities: the European perspective.表皮生长因子受体抑制剂(EGFRI)所致皮肤毒性的临床管理:欧洲视角
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):22-6.
5
Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.表皮生长因子受体抑制剂所致毒性的护理管理
Clin J Oncol Nurs. 2008 Jun;12(3):405-7. doi: 10.1188/08.CJON.405-407.
6
Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.表皮生长因子受体抑制剂(EGFRI)所致皮肤毒性的临床管理:日本视角
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):27-8.
7
Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.与表皮生长因子受体抑制剂相关的皮肤毒性的预防性管理。
Clin J Oncol Nurs. 2011 Oct;15(5):501-8. doi: 10.1188/11.CJON.501-508.
8
Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.表皮生长因子受体抑制剂相关皮肤毒性管理的循证治疗选择
Ann Pharmacother. 2009 Oct;43(10):1658-66. doi: 10.1345/aph.1M241. Epub 2009 Sep 15.
9
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.表皮生长因子受体抑制剂相关的皮肤毒性:临床管理中的一个不断演变的模式
Oncologist. 2007 May;12(5):610-21. doi: 10.1634/theoncologist.12-5-610.
10
Multidisciplinary team-working indicators of good practice in the clinical management of EGFR-inhibitor dermatologic toxicities.
Ann Surg Oncol. 2009 Jan;16(1):224-5. doi: 10.1245/s10434-008-0200-z. Epub 2008 Nov 7.